Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
Mi | What's Going On With Silexion Therapeutics Shares Wednesday? | 1 | Benzinga.com | ||
14.11. | SLXN-Aktie stürzt | 2 | Investing.com Deutsch | ||
14.11. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
14.11. | Silexion Therapeutics Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
01.11. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
01.11. | SLXN stock touches 52-week low at $0.27 amid market challenges | 1 | Investing.com | ||
31.10. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings | ||
09.10. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings | ||
08.10. | SLXN-Aktie erreicht 52-Wochen-Tief bei 0,4 US-Dollar | 1 | Investing.com Deutsch | ||
08.10. | SLXN stock touches 52-week low at $0.4 amid market challenges | 3 | Investing.com | ||
01.10. | Silexion Investigational Pancreatic Cancer Treatment Shows Promise In Animal Studies | 1 | Benzinga.com | ||
01.10. | Silexion Therapeutics Corp - 8-K, Current Report | 4 | SEC Filings | ||
30.09. | SLXN stock touches 52-week low at $0.55 amid market challenges | 1 | Investing.com | ||
30.09. | SLXN-Aktie erreicht 52-Wochen-Tief bei 0,55 US-Dollar | 1 | Investing.com Deutsch | ||
24.09. | Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise | 1 | Benzinga.com | ||
24.09. | Silexion meldet verbesserte Ergebnisse in Bauchspeicheldrüsenkrebs-Studie | - | Investing.com Deutsch | ||
24.09. | Silexion reports improved outcomes in pancreatic cancer trial | 1 | Investing.com | ||
19.09. | Silexion Therapeutics: Vorstandsmitglied tritt zurück | 2 | Investing.com Deutsch | ||
19.09. | Silexion Therapeutics sees board member resignation | 1 | Investing.com | ||
19.09. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
EVOTEC | 9,935 | +0,30 % | KURSEXPLOSION bei Biotech-Aktie! BioNTech, Evotec, Nyxoah | Geht es bei Evotec jetzt doch ganz schnell? Ein Finanzinvestor positioniert sich jedenfalls für eine Übernahme und die Aktie schoss zuletzt kräftig nach oben. Ist damit die Enttäuschung über die Quartalszahlen... ► Artikel lesen | |
QIAGEN | 39,875 | +2,66 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |